Top
FDA's Efforts to Advance the Development of Gene Therapy - Healing Genes
993
post-template-default,single,single-post,postid-993,single-format-standard,mkdf-bmi-calculator-1.0,mkd-core-1.1.1,tribe-no-js,wellspring-ver-1.8,mkdf-smooth-page-transitions,mkdf-ajax,mkdf-grid-1300,mkdf-blog-installed,mkdf-header-standard,mkdf-no-behavior,mkdf-default-mobile-header,mkdf-sticky-up-mobile-header,mkdf-dropdown-slide-from-bottom,mkdf-full-width-wide-menu,mkdf-search-dropdown,elementor-default,elementor-template-full-width,elementor-kit-3486,elementor-page-2078

FDA’s Efforts to Advance the Development of Gene Therapy

Share on facebook
Share on google
Share on twitter
Share on linkedin

Gene therapy has been on the horizon for several decades and has now become a reality in the United States. There are now three approved products: two cell-based gene therapies for cancers of the blood (Kymriah and Yescarta) and one directly-administered gene therapy (Luxturna) for an inherited disorder of the retina of the eye. Numerous gene therapy products are in development to address unmet medical needs, such as those for the treatment of diseases ranging from hemophilia to spinal muscular atrophy. The progress and demand in this field is also evident in the more than 800 active investigational new drug applications for gene therapies on file with FDA.

To keep pace with the remarkable and continuing growth of gene therapy, FDA’s Center for Biologics Evaluation and Research (CBER) has also been growing to take on the challenges of product development and to work with developers to help address those challenges. The National Institutes of Health (NIH) has been and continues to be a leader in the field of gene therapy. Over the years, FDA has developed a comparable cadre of experts, who both review gene therapy applications and conduct applied research relevant to the field. FDA has made it a priority to field a strong bench of highly-skilled and knowledgeable experts in the cutting-edge science behind gene therapy, including genome editing technologies, novel gene delivery methods, and advanced manufacturing technologies.

Read the full story here: https://www.fda.gov/news-events/fda-voices-perspectives-fda-experts/fdas-efforts-advance-development-gene-therapy

More to explorer

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader

CRISPR treatment inserted directly into the body for first time

A person with a genetic condition that causes blindness has become the first to receive a CRISPR–Cas9 gene therapy administered directly into their body. The treatment is part of a landmark clinical trial to test the ability of CRISPR–Cas9 gene-editing techniques to remove mutations that

No Comments

Sorry, the comment form is closed at this time.